<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799396</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00043419</org_study_id>
    <secondary_id>U01 HL074518-01</secondary_id>
    <secondary_id>U01GM074518</secondary_id>
    <nct_id>NCT00799396</nct_id>
  </id_info>
  <brief_title>Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)</brief_title>
  <official_title>Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the most common ways for preventing coronary heart disease (CHD) is to take aspirin or
      clopidogrel. However, studies have shown that not all people respond to these medications.
      The variance in treatment response may be linked to genetics. This study will examine the
      effects of aspirin and clopidogrel in a population whose genes are well known in order to
      determine the role that genes play in treatment responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CHD is the leading cause of death in the United States. Anti-platelet agents lessen platelet
      aggregation and are used commonly to prevent recurrent CHD events. Two of the most common
      anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30% of people do not
      respond to these medications. Evidence indicates that treatment response may be related to
      genetics. The purpose of this study is to determine specific gene variants that predict
      response to aspirin and clopidogrel therapy.

      This study is part of a larger group of studies called the Pharmacogenomics Research Network
      (PGRN). Participants will include the Old Order Amish of Lancaster, Pennsylvania. They are
      well suited for genetic studies because they are a homogenous, closed, founder population.
      Participants will receive 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel
      per day for the next 6 days. On the last day of clopidogrel treatment, participants will take
      a single dose of 324 mg aspirin. Participants will undergo platelet function tests before and
      after clopidogrel alone, and then again after taking clopidogrel plus aspirin. Using the gene
      variation profiles across the genome, researchers will analyze which genes correspond to
      treatment response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Platelet Function in Response to Clopidogrel</measure>
    <time_frame>Measured at baseline, and after clopidogrel treatment</time_frame>
    <description>Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Platelet Function in Response to Clopidogrel Plus Aspirin</measure>
    <time_frame>Measured at baseline, and after clopidogrel plus aspirin treatment</time_frame>
    <description>Baseline minus post clopidogrel/post-aspirin platelet rich plasma (PRP) maximum aggregation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">682</enrollment>
  <condition>Platelet Aggregation Inhibitors</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Overall Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>300 mg on first day, then 75 mg per day for the next 6 days</description>
    <arm_group_label>Overall Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Single dose of 324 mg on the last day of clopidogrel treatment</description>
    <arm_group_label>Overall Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Of Old Order Amish descent

        Exclusion Criteria:

          -  Currently pregnant or less than 6 months have passed since delivery

          -  Has a history of a bleeding disorder or major spontaneous bleed, such as peptic ulcer,
             epistasis, or intracranial bleed

          -  Has severe hypertension, defined by a blood pressure above 160/95 mm Hg, making it
             unethical not to recommend prompt treatment

          -  Takes medications that would affect the outcome(s) to be measured and cannot willingly
             and safely, in the opinion of the treating physician and study physician, discontinue
             these medications for 1 week prior to protocol initiation

          -  Is taking vitamins or other supplements and is unwilling to discontinue their use for
             at least 1 week prior to study

          -  Has a coexisting malignancy

          -  Has a creatinine level greater than 2.0 mg/dl, aspartate transaminase (AST) or alanine
             transaminase (ALT) greater than two times the upper limit of normal, hematocrit less
             than 32%, or a thyroid-stimulating hormone (TSH) less than 0.4 or greater than 5.5
             mIU/L

          -  Has a bleeding disorder or history of gastrointestinal bleeding or other major
             bleeding episode

          -  Is currently taking aspirin, clopidogrel, or other anti-coagulant, such as warfarin,
             heparin, or GPIIb/IIIa antagonists, and have conditions that might place them at
             increased risk from withdrawal of these medications 14 days prior to protocol
             initiation, including history of unstable angina, heart attack, angioplasty (including
             stent placement), coronary artery bypass surgery, atrial fibrillation, stroke or
             transient ischemic attacks, diabetes, or deep vein thrombosis or other thrombosis

          -  Has polycythemia, or thrombocytosis, defined by a platelet count greater than 500,000

          -  Has thrombocytopenia, defined by a platelet count less than 75,000

          -  Has had surgery within the last 6 months

          -  Has an aspirin or clopidogrel allergy

          -  Currently breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan R. Shuldiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Amish Research Clinic</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000391.v1.p1</url>
    <description>dbGaP submission for the PAPI study</description>
  </link>
  <results_reference>
    <citation>Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232.</citation>
    <PMID>19706858</PMID>
  </results_reference>
  <results_reference>
    <citation>Bozzi LM, Mitchell BD, Lewis JP, Ryan KA, Herzog WR, O'Connell JR, Horenstein RB, Shuldiner AR, Yerges-Armstrong LM. The Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study: Variation in Platelet Response to Clopidogrel and Aspirin. Curr Vasc Pharmacol. 2016;14(1):116-24.</citation>
    <PMID>26374108</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis JP, Ryan K, O'Connell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshees AL, Pakzy R, Tanner K, Parsa A, Tantry US, Bliden KP, Post WS, Faraday N, Herzog W, Gong Y, Pepine CJ, Johnson JA, Gurbel PA, Shuldiner AR. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet. 2013 Apr;6(2):184-92. doi: 10.1161/CIRCGENETICS.111.964627. Epub 2013 Feb 7.</citation>
    <PMID>23392654</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics. 2013 Jan;23(1):1-8. doi: 10.1097/FPC.0b013e32835aa8a2.</citation>
    <PMID>23111421</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis JP, Fisch AS, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Shen H, Tanner K, Horenstein RB, Pakzy R, Tantry US, Bliden KP, Gurbel PA, Shuldiner AR. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response. Clin Pharmacol Ther. 2011 Oct;90(4):568-74. doi: 10.1038/clpt.2011.194. Epub 2011 Aug 31. Erratum in: Clin Pharmacol Ther. 2012 Apr;91(4):751.</citation>
    <PMID>21881565</PMID>
  </results_reference>
  <results_reference>
    <citation>Lewis JP, Stephens SH, Horenstein RB, O'Connell JR, Ryan K, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Mitchell BD, Shuldiner AR. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost. 2013 Sep;11(9):1640-6. doi: 10.1111/jth.12342.</citation>
    <PMID>23809542</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2008</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>March 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 28, 2016</results_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Alan Shuldiner</investigator_full_name>
    <investigator_title>Associate Dean for Personalized Medicine; Director, Program in Personalized and Genomic Medicine; Head, Division of Endocrinology, Diabetes and Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
Clopidogrel: 300 mg on first day, then 75 mg per day for the next 6 days
Aspirin: Single dose of 324 mg on the last day of clopidogrel treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Clopidogrel Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="682"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="669"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Clopidogrel Plus Aspirin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="669"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="663"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants were recruited from the Old Order Amish of Lancaster, Pennsylvania. They are well suited for genetic studies because they are a homogenous, closed, founder population.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
Clopidogrel: 300 mg on first day, then 75 mg per day for the next 6 days
Aspirin: Single dose of 324 mg on the last day of clopidogrel treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="682"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Platelet Function in Response to Clopidogrel</title>
        <description>Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation.</description>
        <time_frame>Measured at baseline, and after clopidogrel treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
Clopidogrel: 300 mg on first day, then 75 mg per day for the next 6 days
Aspirin: Single dose of 324 mg on the last day of clopidogrel treatment
PRP ADP 20 = Platelet Rich Plasma ADP-induced (20 microM) aggregation
PRP Collagen 5 = Platelet Rich Plasma Collegan-induced (5 microM) aggregation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Platelet Function in Response to Clopidogrel</title>
          <description>Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation.</description>
          <units>percentage of maximum aggregation change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="669"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRP ADP 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.51" spread="14.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRP Collagen 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.06" spread="15.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Platelet Function in Response to Clopidogrel Plus Aspirin</title>
        <description>Baseline minus post clopidogrel/post-aspirin platelet rich plasma (PRP) maximum aggregation</description>
        <time_frame>Measured at baseline, and after clopidogrel plus aspirin treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
Clopidogrel: 300 mg on first day, then 75 mg per day for the next 6 days
Aspirin: Single dose of 324 mg on the last day of clopidogrel treatment
PRP ADP 20 = Platelet Rich Plasma ADP-induced (20 microM) aggregation
PRP Collagen 5 = Platelet Rich Plasma Collegan-induced (5 microM) aggregation</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Platelet Function in Response to Clopidogrel Plus Aspirin</title>
          <description>Baseline minus post clopidogrel/post-aspirin platelet rich plasma (PRP) maximum aggregation</description>
          <units>percentage of max aggregation change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="663"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRP ADP 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.21" spread="13.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRP Collagen 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.64" spread="14.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>37 days</time_frame>
      <desc>Adverse event data were collected during both intervention periods and for 30 days after the final study visit. There were 6 Adverse Events during the Clopidogrel Treatment Arm and 2 Adverse Events during the Clopidogrel plus Aspirin Arm. This does not exceed the threshold for reporting Other Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Study</title>
          <description>Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
Clopidogrel: 300 mg on first day, then 75 mg per day for the next 6 days
Aspirin: Single dose of 324 mg on the last day of clopidogrel treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="682"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alan R Shuldiner, MD</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>410-706-1623</phone>
      <email>ashuldin@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

